QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)
Publication
, Conference
Schlenk, R; Dombret, H; Amadori, S; Montesinos, P; Levis, M; Sekeres, MA; Cortes, J; Perl, A; Zernovak, O; Mires, D; Ge, N; Zhang, H; Erba, H ...
Published in: ANNALS OF ONCOLOGY
September 1, 2017
Duke Scholars
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Schlenk, R., Dombret, H., Amadori, S., Montesinos, P., Levis, M., Sekeres, M. A., … Erba, H. (2017). QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). In ANNALS OF ONCOLOGY (Vol. 28). Madrid, SPAIN: OXFORD UNIV PRESS.
Schlenk, R., H. Dombret, S. Amadori, P. Montesinos, M. Levis, M. A. Sekeres, J. Cortes, et al. “QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML).” In ANNALS OF ONCOLOGY, Vol. 28. OXFORD UNIV PRESS, 2017.
Schlenk R, Dombret H, Amadori S, Montesinos P, Levis M, Sekeres MA, et al. QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Schlenk, R., et al. “QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML).” ANNALS OF ONCOLOGY, vol. 28, OXFORD UNIV PRESS, 2017.
Schlenk R, Dombret H, Amadori S, Montesinos P, Levis M, Sekeres MA, Cortes J, Perl A, Zernovak O, Mires D, Ge N, Zhang H, Hanyok J, Macintyre S, Gokmen S, Kobayashi K, Erba H. QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2017.
Published In
ANNALS OF ONCOLOGY
EISSN
1569-8041
ISSN
0923-7534
Publication Date
September 1, 2017
Volume
28
Location
Madrid, SPAIN
Publisher
OXFORD UNIV PRESS
Conference Name
42nd European-Society-for-Medical-Oncology Congress (ESMO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis